Pearl River Capital, LLC United Therapeutics Corp Transaction History

Pearl River Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$210.76 - $249.51 $343,538 - $406,701	-1,630 Reduced 20.35%	6,378 $1.47 Million
Q4 2023 Feb 13, 2024	BUY	$214.88 - $256.94 $597,366 - $714,293	2,780 Added 53.18%	8,008 $1.76 Million
Q3 2023 Nov 13, 2023	SELL	$211.82 - $248.24 $6,566 - $7,695	-31 Reduced 0.59%	5,228 $1.18 Million
Q2 2023 Aug 11, 2023	BUY	$205.19 - $232.99 $1.08 Million - $1.23 Million	5,259 New	5,259 $1.16 Million
Q4 2022 Feb 13, 2023	BUY	$205.95 - $280.43 $547,209 - $745,102	2,657 New	2,657 $738,000
Q2 2022 Aug 12, 2022	BUY	$174.81 - $241.14 $254,523 - $351,099	1,456 New	1,456 $343,000
Q4 2021 Feb 11, 2022	SELL	$184.32 - $216.08 $211,415 - $247,843	-1,147 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$179.86 - $214.88 $89,930 - $107,440	-500 Reduced 30.36%	1,147 $212,000
Q2 2021 Aug 13, 2021	BUY	$170.47 - $211.93 $280,764 - $349,048	1,647 New	1,647 $295,000
Q3 2019 Nov 08, 2019	SELL	$74.85 - $85.99 $30,463 - $34,997	-407 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$76.06 - $120.81 $30,956 - $49,169	407 New	407 $32,000

671

42.4M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $17.2B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.